Results 1 to 10 of about 9,765 (234)

Computational design of potent dimeric phenylthiazole NS5A inhibitors for hepatitis C virus [PDF]

Scientific Reports
Hepatitis C virus (HCV) presents a significant global health issue due to its widespread prevalence and the absence of a reliable vaccine for prevention.
Wissal Liman, Mehdi Oubahmane, Nouhaila Ait Lahcen, Ismail Hdoufane, Driss Cherqaoui, Rachid Daoud, Achraf El Allali   +6 more
doaj   +2 more sources

Receptor transporter protein 4 (RTP4)-mediated repression of hepatitis C virus replication in mouse cells. [PDF]

PLoS Pathogens
Hepatitis C virus (HCV) exhibits a narrow species tropism, causing robust infections only in humans and experimentally inoculated chimpanzees. While many host factors and restriction factors are known, many more likely remain unknown, which has limited ...
Michael P Schwoerer, Sebastian Carver, Aaron E Lin, Jianche Liu, Thomas R Cafiero, Keith A Berggren, Serene Dhawan, Saori Suzuki, Brigitte Heller, Celeste Rodriguez, Aoife K O'Connell, Hans P Gertje, Nicholas A Crossland, Alexander Ploss   +13 more
doaj   +2 more sources

Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents [PDF]

, 2014
Hepatitis C virus (HCV) is transmitted between hepatocytes via classical cell entry but also uses direct cell-cell transfer to infect neighboring hepatocytes.
A Owsianka, A Sigal, Aleem Siddiqui, Arvind H. Patel, AS Lok, AW Tarr, B Bartolini, B Sainz Jr, C Hezode, C Lee, C Nathan, C Sarrazin, CL Brimacombe, CM Lange, CT Jones, D Masson, D Trono, EJ Gane, Eric Soulier, F Kuonen, F Poordad, F Poordad, Fei Xiao, François Habersetzer, G Koutsoudakis, H Kwon, H Yan, H Zhu, Heidi Barth, I Fofana, I Fofana, I Fofana, IA Abela, IM Jacobson, Isabel Fofana, J Grove, J Lupberger, J Witteveldt, J Zhong, Jens Bukh, JG McHutchison, JM Gottwein, JM Gottwein, JM Pawlotsky, JM Pawlotsky, JM Pawlotsky, JM Timpe, L Rong, L Zona, Laura Heydmann, LW Meredith, MB Zeisel, MB Zeisel, Michel Doffoël, Mirjam B. Zeisel, MN Zahid, MS Sulkowski, MT Catanese, N Shi, O Lenz, P Zhong, PM Trembling, Q Sattentau, S Haid, T Pietschmann, T Pietschmann, T Wakita, Thomas F. Baumert, TJ Liang, TK Scheel, V Soriano, VD Cataldo, ZY Keck   +72 more
core   +15 more sources

Efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for hepatitis C in Korea: a Phase 3b study [PDF]

The Korean Journal of Internal Medicine, 2023
Background/Aims Despite the availability of direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection in Korea, need remains for pangenotypic regimens that can be used in the presence of hepatic impairment, comorbidities, or prior ...
Jeong Heo, Yoon Jun Kim, Sung Wook Lee, Youn-Jae Lee, Ki Tae Yoon, Kwan Soo Byun, Yong Jin Jung, Won Young Tak, Sook-Hyang Jeong, Kyung Min Kwon, Vithika Suri, Peiwen Wu, Byoung Kuk Jang, Byung Seok Lee, Ju-Yeon Cho, Jeong Won Jang, Soo Hyun Yang, Seung Woon Paik, Hyung Joon Kim, Jung Hyun Kwon, Neung Hwa Park, Ju Hyun Kim, In Hee Kim, Sang Hoon Ahn, Young-Suk Lim   +24 more
doaj   +1 more source

Design and Synthesis of Novel Bis-Imidazolyl Phenyl Butadiyne Derivatives as HCV NS5A Inhibitors

Pharmaceuticals, 2022
In today’s global plan to completely eradicate hepatitis C virus (HCV), the essential list of medications used for HCV treatment are direct-acting antivirals (DAAs), as interferon-sparing regimens have become the standard-of-care (SOC) treatment.
Jehad Hamdy, Nouran Emadeldin, Mostafa M. Hamed, Efseveia Frakolaki, Sotirios Katsamakas, Niki Vassilaki, Grigoris Zoidis, Anna K. H. Hirsch, Mohammad Abdel-Halim, Ashraf H. Abadi   +9 more
doaj   +1 more source

Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure. [PDF]

PLoS ONE, 2016
We aimed to clarify the characteristics of resistance-associated substitutions (RASs) after treatment failure with NS5A inhibitor, daclatasvir (DCV) in combination with NS3/4A inhibitor, asunaprevir (ASV), in patients with chronic hepatitis C virus ...
Jun Itakura, Masayuki Kurosaki, Chitomi Hasebe, Yukio Osaki, Kouji Joko, Hitoshi Yagisawa, Shinya Sakita, Hiroaki Okushin, Takashi Satou, Hiroyuki Hisai, Takehiko Abe, Keiji Tsuji, Takashi Tamada, Haruhiko Kobashi, Akeri Mitsuda, Yasushi Ide, Chikara Ogawa, Syotaro Tsuruta, Kouichi Takaguchi, Miyako Murakawa, Yasuhiro Asahina, Nobuyuki Enomoto, Namiki Izumi   +22 more
doaj   +1 more source

Structure-activity relationships of fluorene compounds inhibiting HCV variants [PDF]

, 2020
Approximately 71 million people suffer from hepatitis C virus (HCV) infection worldwide. Persistent HCV infection causes liver diseases such as chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma, resulting in approximately 400,000 deaths ...
Gadhe, Changdev G., JANG, SUNG KEY, Keum, Gyochang, Kim, Byeong Moon, Kim, Hee Sun, Kohara, Michinori, Lee, Jae Seung, Moon, Heejo, Mun, Jaegon, Pae, Ae Nim, You, Youngsu   +10 more
core   +1 more source

Selection dynamics of HCV genotype 3 resistance-associated substitutions under direct-acting antiviral therapy pressure

Brazilian Journal of Infectious Diseases, 2022
The chronic hepatitis C (CHC) treatment is currently based on the use of direct-acting antivirals (DAAs), and patients infected with hepatitis C virus genotype 3 (GT3) have emerged as a more difficult-to-cure population.
João Paulo Vilela Rodrigues, Guilherme Rodrigues Fernandes Campos, Cintia Bittar, Ana de Lourdes Candolo Martinelli, Marília Silveira de Almeida Campos, Leonardo Régis Leira Pereira, Paula Rahal, Fernanda Fernandes Souza   +7 more
doaj   +1 more source

Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance

Hepatology Communications, 2020
Direct acting antivirals (DAAs) have revolutionized hepatitis C virus (HCV) treatment, but drug resistance could undermine proposed global elimination targets.
Mark W. Douglas, Enoch S.E. Tay, Dao Sen Wang, Adrian T.L. Ong, Caroline Wilson, Amy Phu, Jen Kok, Dominic E. Dwyer, Rowena A. Bull, Andrew R. Lloyd, Tanya L. Applegate, Gregory J. Dore, Anita Y. Howe, Richard Harrigan, Jacob George   +14 more
doaj   +1 more source

Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection

Viruses, 2018
Glecaprevir (an NS3/4A protease inhibitor) and pibrentasvir (an NS5A inhibitor) are potent and pangenotypic hepatitis C virus (HCV) direct-acting antivirals.
Teresa I. Ng, Tami Pilot-Matias, Rakesh Tripathi, Gretja Schnell, Preethi Krishnan, Thomas Reisch, Jill Beyer, Tatyana Dekhtyar, Michelle Irvin, Liangjun Lu, Armen Asatryan, Andrew Campbell, Betty Yao, Sandra Lovell, Federico Mensa, Eric J. Lawitz, Jens Kort, Christine Collins   +17 more
doaj   +1 more source